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Abstract: Lennox-Gastaut syndrome (LGS) is a rare, age-related syndrome, characterized 
by multiple seizure types, a speciﬁ  c electro-encephalographic pattern, and mental regression. 
However, published data on the etiology, evolution, and therapeutic approach of LGS are 
contradictory, partly because the precise deﬁ  nition of LGS used in the literature varies. In the 
most recent classiﬁ  cation, LGS belongs to the epileptic encephalopathies and is highly refractory 
to all antiepileptic drugs. Numerous treatments, medical and non-medical, have been proposed 
and results mostly from open studies or case series have been published. Sometimes, patients 
with LGS are included in a more global group of patients with refractory epilepsy. Only 
6 randomized double-blind controlled trials of medical treatments, which included patients 
with LGS, have been published. Overall, treatment is rarely effective and the ﬁ  nal prognosis 
remains poor in spite of new therapeutic strategies. Co-morbidities need speciﬁ  c treatment. This 
paper summarizes the deﬁ  nition, diagnosis and therapeutic approach to LGS, including not only 
recognized antiepileptic drugs, but also “off label” medications, immune therapy, diet, surgery 
and some perspectives for the future.
Keywords: Lennox-Gastaut syndrome, treatment, VNS, surgery, epileptic encephalopathies, 
LGS, refractory
Introduction
The term Lennox-Gastaut syndrome (LGS) appeared in the literature for the ﬁ  rst 
time in 1969 (Niedermeyer 1969), but this syndrome was actually ﬁ  rst described by 
Lennox and Davis in 1950 and by Gastaut et al in 1966. The International League 
Against Epilepsy (ILAE) Commission (Classiﬁ  cation Epilepsia 1989) classiﬁ  ed LGS 
among the cryptogenic or symptomatic generalized epilepsies, but, more recently, the 
ILAE Task Force classiﬁ  ed it among the age-related epileptic encephalopathies (Engel 
2001). LGS comprises atypical absences with slow spike-and-wave (SW) complexes, 
tonic seizures that are mostly sleep-related, and cognitive deterioration (ILAE). 
However, LGS has also been deﬁ  ned as diffuse SW pattern on electroencephalogram 
(EEG), mental retardation, and multiple types of seizures without reference to age or 
to nocturnal tonic seizures (French et al 2004). This broader deﬁ  nition, mostly used 
in the US, may include for example, Dravet syndrome, Doose syndrome, or focal 
cryptogenic epilepsies, especially of frontal lobe origin. According to Genton et al 
(2000), EEG criteria should include not only bilateral slow SW but also 10–20 Hz 
epileptic fast rhythms, predominantly in sleep. Furthermore, this syndrome belongs 
to the age-related epileptic encephalopathies and starts during childhood. When using 
these full criteria, LGS appears to be rare.
Largely as a result of the different deﬁ  nitions, the literature presents, or seems 
to present, contradictory data about the frequency of seizure types, epidemiology, 
treatment options, prognosis, and long term evolution of LGS. Furthermore, results of 
clinical studies are difﬁ  cult to compare in terms of efﬁ  cacy and most of them, especially 
randomized studies, do not cover more than a few weeks (Hancock and Cross 2003). Neuropsychiatric Disease and Treatment 2008:4(6) 1002
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Treatment is rarely effective and the ﬁ  nal prognosis remains 
poor in spite of new therapeutic strategies, with persistent 
seizures, mental retardation/deterioration, and behavioral 
problems.
Epidemiology-etiology
LGS is rare, with an annual incidence of 0.2–2.8/10,000 births 
in European countries (Heiskala 1997) but the prevalence 
of LGS is higher (5% of all epilepsies and about 10% of 
childhood epilepsy) because of its refractory characteristics 
(Trevathan et al 1997).
LGS can appear de novo in cryptogenic cases (about 
30%) or be the result of brain injury of various etiologies 
(pre- or peri-natal insult, infection, various malformations 
including dysplasia, and brain tumor) in symptomatic 
cases. In these latter cases, LGS is often (18%–50%, 
mean 30%) preceded by West syndrome or focal seizures 
(Glauser 2004).
LGS starts between 2 and 8 years (peak 3–5 years), 
slightly later in cryptogenic cases than in symptomatic ones, 
and is more common in boys than in girls. The age-related 
link suggests an inﬂ  uence of brain maturation on symp-
toms and disease evolution. Indeed, the usual age of onset 
corresponds with maturation of the frontal lobes and most of 
the clinical and EEG signs have a frontal lobe semiology.
Recently, a defect in the mitochondrial chain has been 
suggested as the cause of LGS (Lee et al 2008) and this 
metabolic pathway should be carefully explored in the 
so-called cryptogenic cases.
Diagnosis
LGS is characterized by an electroclinical triad: Multiple 
seizure types, speciﬁ  c EEG pattern and mental slowing 
and/or regression. However, etiological diagnosis and 
identiﬁ  cation of co-morbidities are important for correct 
global management.
Clinical features
The ﬁ  rst clinical sign, at least in cryptogenic cases, is often the 
occurrence of abrupt falls. These are followed by intractable 
generalized seizures, including myoclonic, tonic, atonic, and 
atypical absences and by mental slowing then regression. 
Some patients may have tonic and/or non-convulsive status 
epilepticus (SE). These episodes of SE may aggravate or 
precipitate cognitive decline.
The most disabling seizures are falls, sometimes 
called “epileptic drop attacks” and may be secondary to 
atonic or tonic seizures and, more rarely, to myoclonic or 
myoclonic-atonic seizures, these being more typical of 
Doose syndrome. The causes of these epileptic drop attacks 
are difﬁ  cult to differentiate clinically and they can result in 
recurrent injuries and additional handicap. The frequency of 
drop attacks has been used as the primary outcome in most 
randomized studies in LGS. Tonic seizures may appear 
with variable severity from subtle symptoms to generalized 
stiffness and falls and may be triggered or worsened by 
benzodiazepines (BZDs) (Tassinari et al 1972; Dimario and 
Clancy 1988).
Atypical absences are characterized by an alteration 
in, rather than a loss of, consciousness. They may be 
accompanied by other subclinical signs, such as discreet loss 
of tonus, subtle myoclonus, head nodding.
Myoclonic seizures in LGS are considered rare by some 
authors but as an important and difﬁ  cult to treat part of the 
syndrome by others. However, if this type of seizure is 
predominant, an alternative diagnosis should be suspected. 
These seizures may be aggravated by some antiepileptic 
drugs (AEDs) (Feucht and Brantner-Inthaler 1994).
Fewer than 50% of patients have focal seizures and, 
globally, tonic-clonic seizures are rare (Dulac 2001), 
although, again, other authors consider them as frequent and 
resistant to medical treatment.
Patients with LGS will have at least one episode 
of status epilepticus in their history, mainly atypical 
absence status or tonic status with subtle signs. Some 
AEDs can precipitate status, especially benzodiazepines 
(BZDs) (Tassinari et al 1972).
Non-convulsive status epilepticus (NCSE) occurs in 
more than 50% of patients. Typically, NCSE appears as 
subcontinuous atypical absences repeatedly interrupted by 
brief tonic seizures or as subtle tonic status with progressive 
reduction of motor manifestations and prolonged obtundation 
with mild myoclonias.
Progressively, after seizure onset, slowing or arrest of 
cognitive development occurs with behavioral problems in 
about 50% of cases, including hyperactivity, aggressiveness, 
autistic traits. These features are more marked in early onset 
or symptomatic LGS.
Neurological examination is non specific, from 
normal to lateralized, depending on the underlying 
etiology.
Later in the disease, it can be difﬁ  cult to differentiate 
problems related to LGS, from those occuring as a result of 
AEDs, or because of numerous falls or frequent SE.
Teenagers with a history of LGS may continue to have 
atypical absences, generalized tonic-clonic seizures and atonic Neuropsychiatric Disease and Treatment 2008:4(6) 1003
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seizures, but while some authors report that tonic seizures 
become rare to absent, for others, tonic seizures remain the major 
problem (Roger et al 1989, Dulac and Engel ILAE link).
Electroencephalogram (EEG) and 
magnetoencephalogram (MEG) features
Slow (2.5 Hz) SW, ﬁ  rst described by Gibbs et al (1939), 
is the most prominent feature in interictal awake EEG. 
The average age of onset of slow SW is 8.2 years, with a 
mean duration of 8.6 years. However, EEG criteria should 
also include 10–20 Hz epileptic recruiting or fast rhythm, 
appearing principally in sleep (Genton et al 2000).
Generalized polySW and lower voltage of short duration 
fast activities are usual during slow sleep. Photic stimulation has 
no impact on the EEG while hyperpnea may exacerbate slow 
SW. Focal paroxysmal discharges or slowing may be recorded 
in symptomatic LGS, related to the underlying pathology.
The ictal EEG pattern depends on the seizure type. 
Atypical absences are recorded during slow SW but they are 
sometimes difﬁ  cult to distinguish from the background from 
a clinical and EEG point of view. Myoclonic seizures are 
associated with bilateral and symmetrical SW and polySW 
whereas fast activities are typical of tonic seizures.
With age and disease evolution, EEG changes and 
multifocal spikes may be seen as well as diffuse or localized 
slowing. Diffuse slow SW tend to be “frontalized”.
MEG records the magnetic signal generated by the 
intraneuronal current. This signal is not attenuated or 
distorted as is the electric signal. MEG, with up to more than 
100 channels, is more powerful in dipole localization and in 
evaluating transcallosal spread in generalized epileptiform 
discharges due to secondary bisynchrony. In most cases, 
MEG information is combined with MRI images and can 
provide anatomic localization of interictal epileptiform 
activities (Technology Evaluation Center 2003).
Anecdotal case reports (Sakurai et al 2006) offer some 
support for the use of MEG in “atypical” LGS, particularly 
if surgical treatment is being considered.
Imaging (positon emission tomography 
(PET) scan, magnetic resonance imaging 
(MRI) features
The MRI is by deﬁ  nition, normal in cryptogenic cases, ie, in 
about 30% of cases. However, high MRI resolution may show 
small amounts of cortical dysplasia in a previously normal 
MRI. Occasionally, a brain tumor (Quarato et al 2002) or 
broad dysplasia (You and Lee 2007b) can be found with 
MRI and consequently surgery may be offered as a curative 
treatment. Usually, symptomatic cases have a worse 
prognosis than cryptogenic LGS. Goldsmith et al (2000) did 
not ﬁ  nd (in a retrospective study of 107 conﬁ  rmed cases of 
LGS from 245 presumed cases) any prognostic value of MRI 
on seizure outcome; 74 of the 107 patients were followed-up 
for 3 years. However, these investigators divided their LGS 
patients into three groups: cryptogenic, symptomatic and 
indeterminate. According to the ILAE, only cryptogenic and 
symptomatic cases are recognized. Based on the descriptions 
given by Goldsmith et al the indeterminate cases belong to 
the cryptogenic group and this multiple subdivision gives 
less weight to the statistics.
PET scan may show focal hypometabolism even in 
cryptogenic cases (Gur RC et al 1982; Ferrie et al 1996). 
Therefore, this imaging technique is recommended for 
presurgical evaluation, even if the MRI is normal or the EEG 
shows multifocal abnormalities.
Differential diagnosis
Clinically, the differential diagnosis of drop attacks is the 
major concern. The slow SW pattern represents another 
challenge for diagnosis on awake EEG.
Some epileptic syndromes or clinical situations must be 
excluded:
–  Atypical cases of continuous SW during slow sleep with 
akinetic absence status and/or negative myoclonia
– Doose  syndrome
– Dravet  syndrome
– Toxic  encephalopathy
–  Metabolic diseases, such as Glut-1 deﬁ  ciency syndrome 
(De Vivo et al 1991; Wang et al 2005) and pyruvate 
dehydrogenase deﬁ  ciency (Wexler et al 1997),
–  Focal or multifocal epilepsy with secondary bisynchrony 
on EEG
–  Late onset epileptic spasms
It is, therefore, mandatory to record a sleep EEG and, if 
necessary, video-EEG monitoring or polygraph recording, 
before making a diagnosis of LGS.
It is not rare (up to 40% of secondary generalized 
epilepsies in childhood) (Camﬁ  eld and Camﬁ  eld 2007) for 
children with mental handicap, slow SW and several seizure 
types to remain with an undetermined diagnosis despite full 
investigation.
Evolution and prognosis
Overall prognosis remains poor in spite of new therapeutic 
strategies. About 90% of patients become mentally Neuropsychiatric Disease and Treatment 2008:4(6) 1004
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handicapped with a progressive deterioration in IQ, and 
more than 80% continue to experience seizures throughout 
life; tonic seizures tend to be prominent over time for 
some authors, while for others tonic-clonic or atonic 
seizures, or atypical absences persist. Psychiatric and 
behavioral problems with autistic features are common 
and sometimes require intensive treatment. Mechanisms of 
deterioration have been proposed (Blume 2004) but remain 
hypothetical.
The mortality rate is high, but varies in the literature from 
about 3%–7%, mostly related to accidents (Glauser 2004), 
to 25% due to underlying neurological conditions (Camﬁ  eld 
and Camﬁ  eld 2007).
Recently, Yamatogi and Ohtahara (2006) reported on the 
long-term evolution of severe epileptic encephalopathies, and 
suggested a new syndrome, the “severe epilepsy with multiple 
independent spike foci” as the ﬁ  nal evolution of LGS.
Data on evolution and prognosis are, however, often 
contradictory, mainly due to different deﬁ  nitions of LGS not 
only over time but also in different countries.
Treatment
Chronic medical treatment remains disappointing and only 
six randomized double-blind controlled trials (The group 
of Cinromide 1989; Inanaga et al 1989; Felbamate study 
group 1993; Sachdeo et al 1999; Motte et al 1997; Glauser 
et al 2000) have been published; of these, 4 gave signiﬁ  cant 
results (Table 1). Other randomized controlled studies have 
been published in patients with refractory epilepsy, some 
of them suffering from LGS, but individual results cannot 
be extrapolated from the global data (Battaglia et al 1991; 
van Rijckevorsel et al 1994). Treatment of the multiple 
seizure types often requires broad spectrum AEDs and/or 
polypharmacy. AEDs that are effective for one seizure type 
may worsen another or provoke SE. Furthermore, there is 
no speciﬁ  c experimental model for syndromes such as LGS, 
and rodent models cannot mimic the complexity of LGS for 
effective drug development (Jensen 2006).
Co-morbidities often necessitate speciﬁ  c treatments, 
eg, psychotropic drugs, which may secondarily aggravate 
seizures. In addition, seizures are often very frequent and 
difﬁ  cult to count because most are subtle. The seizures 
may also be difﬁ  cult to classify (tonic versus atonic or 
tonic-clonic) and slow disease ﬂ  uctuations over several 
weeks or months may occur independently of drug treatment. 
For these reasons, there may be considerable inter-observer 
differences in reporting of the numbers and types of seizures 
in individual patients, which may inﬂ  uence study results and 
analysis over the relatively short-term evaluation of clinical 
studies (average of 3 months).
Occasionally surgery, eg, corpus callosotomy, vagus nerve 
stimulation (VNS) (Patwardhan et al 2000) or resection of an 
underlying focalized lesion, may be beneﬁ  cial, and non-AED 
medical treatments, eg, ketogenic diet or research treatments 
such as deep brain stimulation (DBS) (Velasco et al 1991) 
or intraveinous immunoglobulin (IVIG) (van Engelen et al 
1994b; Duse et al 1996; van Rijckevorsel 1999), may offer 
some improvement in selected cases.
Table 1 Comparison of double-blind, randomized, placebo-controlled studies in LGS
Authors Patients Study design Results
FBM study group 
1993 Jensen 1994; 
Delanty and French 
1998
73* participants (37 FBM) 
ﬁ  nal results for 50 (28 FBM)
age: 4–36 years 45 mg/kg/day
or 3600 mg/day
Placebo controlled multicenter 
randomized duration: 70 days
19% total seizure reduction (37 FBM) 
34% atonic seizure reduction (37 FBM) 
44% atonic seizure reduction in the 
28 FBM patients
Motte et al 1997; 
Delanty and French 
1998
179* (79 LTG) results
for 169 (78 LTG) age: 3–25 years
Multicenter randomized
double-blind placebo 
controlled duration: 16 weeks
34% median major type seizure 
reduction 32% median total seizure 
reduction 37.3% of 50% RR for drop 
attacks
Sachdeo et al 1999 112 participants results for
97* (48 TPM) seizure onset age 
1–30 years
multicenter, randomized 
double-blind, 
placebo-controlled duration: 
11 weeks
33% have a 50% seizure reduction 
14.8% median seizure reduction 
20.6% total seizure reduction
Glauser et al 2005 138* patients (74 RUF)
Age : 4–37 years
Multicenter, double-blind, 
placebo controlled
42.5% median seizure reduction 
and for RR for tonic-atonic seizures 
53.4% with improvement in seizure 
reduction
* = broad deﬁ  nition.
Abbreviations: FBM, felbamate; LGS, lennox-gastaut syndrome; LTG, lamotrigine; RUF, ruﬁ  namide; TPM, topiramate.Neuropsychiatric Disease and Treatment 2008:4(6) 1005
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Chronic medical treatment
“Old” antiepileptic drugs
Benzodiazepines (BZDs)
BZDs, since their development in the 1970s, remain among 
the most powerful available AEDs, particularly in SE. They 
can be divided into two groups: 1,4-BZDs (clonazepam, 
clorazepate, diazepam, nitrazepam, lorazepam) and 
1,5-BZDs (clobazam). The BZDs act on the BZD receptor, 
as agonists, to potentiate gamma-aminobutyric acid (GABA) 
neurotransmission, on voltage sensitive calcium channels and 
on Na+ channels. They reportedly increase the frequency of 
chloride channel opening and act by suppressing the spread of 
seizure activity but not by abolishing the abnormal discharge 
of the epileptic focus. BZDs reduce the inhibitory output of 
the reticular neurons and, therefore, prevent absence seizure 
activity. BZDs have been used as acute parenteral or rectal 
agent (diazepam, lorazepam, midazolam) or for chronic 
oral use (clobazam, clonazepam, clorazepate, nitrazepam) 
(Vassella et al 1973; Muller and Lenard 1988; Trimble 2002). 
BZDs remain, in most guidelines, the treatment of choice 
for acute or subacute seizures, but should be avoided, 
particularly the 1,4-BZDs, for prolonged therapy because of 
tolerance, somnolence, risk of withdrawal seizures, increased 
bronchial or oral secretions, etc. However, in practice, they 
are still widely prescribed with the speciﬁ  c risk in LGS of 
precipitating tonic SE (Dimario and Clancy 1988).
Clobazam (CLB)
CLB, the only 1,5-BZD, works, in animal models, by intensifying 
GABA-mediated inhibitory effects and by increasing the activity 
of glutamate transporters. CLB is metabolized by CYP3A4 
and 2C19 to the active metabolite-N-Desmethylclobazam 
(NCLB). This BZD presents several advantages over the 
1,4-BZDs, especially for add-on therapy, including a: rapid 
onset of action, broad spectrum of activity, long half-life, 
and few important drug interactions. Vajda et al (1985) studied 
the effects of CLB in patients with refractory epilepsy, some 
of them suffering from LGS; however, it is not possible to 
analyze the effects on patients with LGS independently of 
the global results. CLB may have fast and impressive results 
(Farrell 1986; Munn and Farrell 1993) and is better tolerated 
than other BZDs. According to the litterature, long-term 
efﬁ  cacy can be maintained in 40 to 60% of patients with 
refractory epilepsy (Ng and Collins 2007). Schmidt and 
Bourgeois (2000) recommend the temporary add-on use 
of CLB while modifying or reducing doses of concomitant 
AEDs. In a Phase 2 trial, CLB signiﬁ  cantly reduced drop 
seizures compared to baseline. A phase 3 trial is ongoing 
in patients with LGS (on May 1, 2008: http://clinicaltrials.
gov/ct2/results?term=clobazam; clinicaltrials.gov identiﬁ  er: 
NCT00518713). In 2008, CLB has been designated as an 
orphan drug by the FDA for patients with LGS.
Clonazepam (CZP)
This AED was considered as one of the drugs of choice for 
the management of myoclonic epilepsies, including LGS 
(Pinder et al 1976). Unfortunately, tolerance develops in 
approximately 30% of patients, even after adjustment of 
dosage. Withdrawal seizures are frequent and sometimes 
severe in case of irregular intake or (non) accidental 
withdrawal. Furthermore, CZP may precipitate the 
occurrence of tonic-clonic seizures and tonic (Tassinari et al 
1972, Dimario and Clancy 1988) or absence SE. The 
most frequent side effects are drowsiness in about 50% of 
patients and ataxia in approximately 30%. Seizures related 
to drowsiness may, therefore, be increased. Furthermore, 
signiﬁ  cant interactions exist with other AEDs and other 
common medications, including cimetidine, disulﬁ  ram, 
oral contraceptives, digoxin, and rifampicin. CZP should, 
therefore, not be prescribed for chronic use, or only as a last 
option. Nevertheless, this AED is still often used as a ﬁ  rst 
or second option, partly because of its low cost.
Clorazepate (CLZ)
This BZD is prescribed in refractory epilepsies (Trimble 2002) 
and some excellent results have been published (Naidu et al 
1986), but there are no speciﬁ  c data for LGS and no controlled 
data. This BZD is mostly prescribed as a second line AED 
in focal seizures.
Diazepam (DZP), lorazepam (LZP),
midazolam (MDL)
These BZDs are mainly used for acute, prolonged or cluster 
seizures and SE. They can be administered intrarectally, by 
intravenous infusion or, for midazolam, by intramuscular, 
intranasal or intrabuccal routes (Scott et al 1999).
Nitrazepam (NZP)
This BZD tends to be used in pediatric epilepsy, speciﬁ  cally 
in infantile spasms and LGS. However, only uncontrolled 
data are available (Chamberlain 1996; Farrell 2002; Hosain 
et al 2003) and excessive sedation has been described in 
numerous children.
Carbamazepine (CBZ), oxcarbazepine (OXC)
These AEDs act mainly by inhibiting the voltage-activated 
Na+ channels. OXC differs from CBZ by also inhibiting Neuropsychiatric Disease and Treatment 2008:4(6) 1006
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voltage-gated Ca++ channels. CBZ and OXC can control 
tonic-clonic and focal seizures and reduce tonic seizures, but 
aggravation of atypical absences and/or myoclonic seizures 
is common (Delanty and French 1998; Perucca et al 1998; 
Schmidt and Bourgeois 2000; Dulac 2001).
There are no speciﬁ  c studies with OXC in LGS.
Cinromide
In preclinical studies, cinromide seems to offer a broad 
spectrum of action with inhibitory effects like those of 
phenytoin (PHT) and CBZ but also effects similar to 
valproate (VPA) and ethosuximide (ESM).
In the 1980s, open-label studies (Lockman et al 1980) 
reported the efﬁ  cacy of cinromide in the treatment of LGS. 
The first multi-center double-blind placebo-controlled 
clinical trial of treatment for LGS was designed (The group 
of Cinromide 1989) and 73 patients, 2–18 years old (data 
available only for 56 participants, 26 on study drug) were 
enrolled. However, the study was terminated prematurely 
when it was clear that cinromide was not superior to placebo 
and further development of this drug was stopped.
Succinimides
Succinimides reduce the low threshold T-type Ca++ currents 
in thalamic neurons but also decrease the persistent Na+ and 
Ca++-activated K+ currents in thalamic and layer V cortical 
pyramidal neurons. More recently, succinimides, particularly 
ESM have been shown to reduce the elevated glutamate 
levels present in the primary motor cortex in animals with 
absence seizures.
–  Methsuximide has been used as adjunctive treatment 
of atypical absences, tonic and myoclonic seizures 
associated with LGS (Browne 1995). However, only 
anecdotal results are available.
–  Trimethadione has considerable efﬁ  cacy against absence 
seizures. Lennox (1945) emphasized that trimethadione 
was also effective against the atypical absences and 
myoclonic and atonic seizures of LGS. This drug is no 
longer used because of its toxicity.
–  ESM is considered as a fourth-line and adjunctive therapy 
in by Schmidt and Bourgeois (2000) for its effects on 
controlling atypical absences and improving myoclonic 
and atonic seizures.
Phenobarbitone (PB), primidone (PRM)
Barbiturates such as PB act as positive allosteric modulators 
of GABA-A receptors, but in a different way than BZDs. In 
addition, they also act on other ion channel systems, including 
Ca++ and Na+ channels.
In a double-blind crossover trial (Vassella et al 1978), VPA 
was compared with PB in 17 epileptic children with LGS. 
VPA appeared to be somewhat more effective than PB but 
the difference was not statistically signiﬁ  cant. PB may worsen 
behavioral problems (Delanty and French 1998) in children 
and has cognitive and sedative side effects. These AEDs 
should be avoided even though they can control tonic-clonic 
seizures (Vassella et al 1973; Muller and Lenard 1988).
Phenytoin (PHT)
PHT, like CBZ, inhibits the voltage-activated Na+ channels 
but also the ﬂ  ux of Ca++ ions across synaptic and other 
membranes. PHT can control tonic-clonic seizures and 
reduce tonic seizures in LGS, but aggravation of atypical 
absences and myoclonic seizures is common (Schmidt and 
Bourgeois 2000; Dulac 2001; Sazgar and Bourgeois 2005) 
and chronic use should, therefore, be avoided. Acute use may 
be necessary to manage convulsive SE.
Valproate (VPA)
VPA acts by several mechanisms: It potentiates GABA-ergic 
inhibitory effects; interacts with the metabolism of gamma-
hydroxybutyrate, a metabolite of GABA; suppresses 
N-methyl-D-aspartate (NMDA)-evoked depolarization; and 
inhibits Na+ channels. At higher concentrations, VPA may 
affect calcium and potassium channels (Johannessen and 
Johannessen 2003). Other potential mechanisms have also 
been described recently (Xu et al 2007).
This broad spectrum AED is considered by most 
practitioners and authors to be the drug of choice in this 
multiseizure type syndrome (Wheless et al 2005). However, 
VPA alone is rarely sufﬁ  cient and children with polypharmacy 
are at greater risk of serious hepatic toxicity or pancreatitis. 
Only one double-blind study (Vassella et al 1978) has been 
conducted with 17 patients, crossed-over with PB. The 
results were not statistically signiﬁ  cant although there was 
a trend in favor of VPA. Other studies (Jeavons et al 1977) 
involved patients with a mixture of epileptic syndromes, 
including LGS, and it is sometimes difﬁ  cult to extract results 
speciﬁ  c to LGS. Moreover, these studies were observational 
or retrospective.
Vigabatrin (VGB)
VGB’s main actions are on the GABA-ergic synapse as 
an irreversible inhibitor of the GABA-degrading enzyme, 
GABA transaminase. This single mode of action can explain 
the frequent worsening of seizures in LGS. Published results 
are variable (Luna et al 1989, Livingston et al 1989), but 
VGB may aggravate myoclonic seizures (Dulac et al 1991) Neuropsychiatric Disease and Treatment 2008:4(6) 1007
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while 85% of children experiencing a 50% reduction in 
total seizure frequency at least in the short term (Feucht 
and Brantner-Inthaler 1994). Other authors (Schmidt and 
Bourgeois 2000) consider VGB as a fourth-line treatment. 
At the present time, in most countries, the use of this drug 
is restricted to West syndrome because of the occurrence of 
visual ﬁ  eld defects.
Newer antiepileptic drugs
Felbamate (FBM)
FBM, a carbamate-type anticonvulsant, showed a broad 
spectrum and several modes of action (White et al 2007) 
in preclinical trials (ability to limit the spread of seizure 
activity and to raise seizure threshold, to modulate the glycine 
NMDA receptor and to be a weak inhibitor at the BZD 
GABA-A receptor). This AED was the ﬁ  rst to be approved for 
adjunctive therapy in LGS after a double-blind, randomized, 
placebo-controlled study showed a signiﬁ  cant effect on 
“major” seizures (FBM study group 1993). Open studies 
(Dodson et al 1993; Jensen 1994; Gay et al 1995; Avanzini 
et al 1996; Eriksson et al 1998) and another double-blind 
study (Siegel et al 1999) conﬁ  rmed these initial results.
Unfortunately, FBM is intensively metabolized and severe 
life-threatening adverse events (aplastic anemia and hepatic 
failure) appeared a few months after approval, limiting FBM 
use since 1994 to cases refractory to other AEDs. A review 
of the past 10 years of clinical experience (more than 35,000 
new cases) has demonstrated that the risk/beneﬁ  t of FBM 
therapy supports its use as an important add-on option for 
patients with highly refractory epilepsies (Pellock et al 2006). 
However, in some countries, its use has been restricted to 
refractory LGS despite efﬁ  cacy in focal epilepsy.
Lamotrigine (LTG)
LTG, with its Na+ channel blocking actions, was initially 
introduced for add-on therapy of focal seizures in adults, but 
it was rapidly demonstrated that it was a broad spectrum AED. 
Additional mechanisms of action have been demonstrated, 
including stabilizing neural membranes and inhibiting 
the release of excitatory (glutamate and aspartate) neural 
transmitters (White et al 2007). Current data demonstrate 
efﬁ  cacy against focal seizures, tonic-clonic seizures, tonic 
seizures, absence seizures, and atonic seizures. More recently 
(Cianchetti et al 2002; Conry 2004), LTG was shown to 
be effective in West syndrome. From the early 1990s, 
apparent efﬁ  cacy in open-label studies (Timmings et al 
1992; Schlumberger et al 1994; Donaldson et al 1997; Farrell 
et al 1997) in LGS led to double-blind, randomized clinical 
trials (Motte et al 1997; Eriksson et al 1998), conﬁ  rming 
a statistically signiﬁ  cant improvement, at least in major 
seizures. Worsening or no improvement of myoclonic jerks 
has been reported in LGS (Donaldson et al 1997; Dulac and 
Kaminska 1997) and related syndromes.
Most children with LGS already receive one or more 
AED, and the addition of LTG can be difﬁ  cult if they are 
already being treated with an enzyme-inducing AED, VPA 
or both. Co-medication may have a dramatic effect on the 
half-life of LTG (and consequently on efﬁ  cacy and acute 
adverse events), and on safety issues, particularly the risk 
of rash, which is as high as 5% to 10% in younger patients. 
Titration of LTG thus requires careful attention, especially 
in children.
Topiramate (TPM)
Like LTG, TPM has several modes of action (modulation of 
voltage-dependent Na+ channels, potentiation of GABA-induced 
chloride ﬂ  uxes, and decreased glutamatergic excitability 
[blockade of kainate glutamate receptors]). TPM was initially 
approved for use in focal seizures in adults, and later also for 
children and in generalized tonic-clonic seizures. However, 
TPM also showed efﬁ  cacy in drop attacks associated with 
LGS in open (Uvebrandt and Bauzière 1994; Sachdeo et al 
1996; Glauser et al 1997; Ritter et al 1998) and in double-blind 
studies of patients with refractory epilepsies, including LGS 
(Glauser et al 1998). In 1999, a double-blind randomized 
study (Sachdeo et al 1999) conﬁ  rmed the efﬁ  cacy of TPM 
in reducing the frequency of atonic seizures associated with 
LGS. Additional studies and small series have conﬁ  rmed the 
long-term efﬁ  cacy of TPM (Tartara et al 1996; Guerreiro 
et al 1999; Glauser et al 2000; Coppola et al 2002; Mikaeloff 
et al 2003; Al Ajlouni et al 2005) with improvement in 
quality of life (QOL) associated with better seizure control 
(Alva-Moncayo and Ruiz-Ruiz 2003). The overall safety 
proﬁ  le makes this drug option appealing when compared 
to the possible life-threatening adverse events of FBM 
and LTG. Rapid titration is possible in emergencies, but 
aggravates central nervous system (CNS) adverse events, 
including somnolence, mental slowing, fatigue, and ataxia. 
A slow dose-titration schedule is, therefore, usually necessary 
to avoid particularly cognitive and language problems 
worsening with a rapid dose escalation. Weight decrease 
could be an issue in some children, but can be welcome in 
others. Unexpected adverse events have been published, such 
as acute glaucoma (Banta et al 2001) or oligohidrosis (Arcas 
et al 2001). However, to date, TPM has not been associated 
with any life-threatening adverse events.Neuropsychiatric Disease and Treatment 2008:4(6) 1008
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Ruﬁ  namide (RUF)
RUF is a novel compound with anticonvulsant activity, 
a triazole derivative structurally unrelated to currently 
marketed AEDs, and of largely unknown mechanisms of 
action (Arroyo 2007; Kluger and Bauer 2007). RUF probably 
acts by an inhibition/modulation of Na+-dependent action 
potentials in neurons and by inhibitory effect at the GluR5 
subtypes at high concentrations (Perucca et al 2008). The 
protective index of RUF, in animals, is much higher than 
that of most common AEDs. RUF has a broad spectrum 
of anti-epileptic actions including focal and generalized 
seizures. RUF is extensively metabolized by non-CYP450 
systems. The most commonly reported adverse effects are 
CNS related (headache, somnolence, fatigue and tremor). 
Randomized, placebo-controlled trials in the 1990s showed 
efﬁ  cacy against focal seizures. The development of RUF 
for neuropathic pain and epilepsy was stopped by Novartis 
in 2001. This drug was further investigated in LGS in a 
single (Hakimian et al 2007) and a double-blind (Glauser 
et al 2005), randomized, placebo-controlled study which 
showed a statistically significant efficacy in reducing 
seizures associated with LGS: there was a 42.5% median 
seizure reduction and 42.5% of responders (50% seizure 
reduction) for tonic-atonic seizures, while 53.4% of patients 
had some reduction in seizure frequency.
Antiepileptic and other drugs used
“off label” in LGS
Acetazolamide
Acetazolamide, a carbonic anhydrase inhibitor, is known to 
have efﬁ  cacy against multiple types of seizures and is usually 
well-tolerated (Lombroso et al 1956; Holowich and Thurston 
1958; Lombroso and Forsythe 1960). Acetazolamide could, 
therefore, be useful as add-on therapy in LGS. However, newer 
and more powerful AEDs, such as TPM, also inhibit carbonic 
anhydrase, making acetazolamide less interesting.
Allopurinol (ALL)
Some reports in the “older” literature suggested an antiepileptic 
effect of the xanthine oxidase inhibitor, ALL, when added to 
traditional drugs (Marrosu et al 1990). Six patients with LGS, 
from 41 epileptic non-hyperuricemic subjects, aged 2–54 years, 
already medicated with 2 or 3 AEDs were treated with ALL 
in doses ranging from 150 to 300 mg daily (DeMarco and 
Zagnoni 1986). A progressive decrease in the weekly seizure 
frequency was observed in two-thirds of the cases in this 
open-label study. Further efﬁ  cacy has never been proven.
Bromide
Bromide, introduced in 1857, was, in fact, the ﬁ  rst effective 
antiepileptic agent, long before the discovery of PB in 1912. 
The mechanisms of action are largely unknown but bromide 
could act via GABA-activated chloride channels, leading 
to stabilization and decreased sensitivity to epileptic foci. 
The major problem with bromide is in obtaining a positive 
balance between seizure suppression and the occurrence 
of adverse events. After the introduction of newer AEDs, 
bromide was largely forgotten. In the 1990s, it was tested 
again in several severe seizure disorders, including LGS 
(Woody 1990). Results were encouraging, but studies were 
only short term and without a control group. This drug is still 
used in catastrophic epilepsies, such as malignant migrating 
partial seizures in infancy or Dravet syndrome (Tanabe et al 
2008), with inconsistent results.
Flunarizine (FLN)
FLN, a calcium channel blocker, was shown to have 
electrophysiological effects in vitro in the late 1980s, suggesting 
anticonvulsant efﬁ  cacy. In the early 1990s, FLN was tried in a 
few difﬁ  cult-to-treat epilepsy patients with some success. One 
placebo-controlled, cross-over study (Battaglia et al 1991) 
looked at the effect of FLN in 20 patients with refractory 
epilepsy, 6–18 years old, 10 of whom had LSG. Thirteen 
patients completed the study with a 30%–60% reduction in 
seizure frequency. This drug is no longer used in epilepsy.
Gabapentin (GBP) and pregabalin (PRG)
GBP synthesized as a GABA-ergic drug does not interact with 
the GABA receptors but is a ligand of the α2δ voltage-activated 
Ca++ channels resulting in inhibition of glutamate release at 
excitatory synapses. PRG is an analog of GBP with the same 
binding afﬁ  nity. The clinical proﬁ  le of GBP in epilepsy patients 
is restricted to the treatment of focal seizures, with or without 
secondary generalization. It has been tried in other syndromes 
and Vossler (1996) reported a worsening of seizures when 
using GBP in LGS. There is no study of PRG in LGS but this 
AED may provoke myoclonus (Modur and Milteer 2008).
Levetiracetam (LEV)
SV2A, a synaptic vesicle protein, has recently been 
identiﬁ  ed as the likely target of LEV, making this a new and 
unique mechanism of action among the AEDs (Kaminski 
et al 2008). LEV was added-on in 6 patients with LGS in a 
retrospective survey (De Los Reyes et al 2004). Myoclonic 
seizures were the best controlled while tonic seizures 
remained unchanged. Irritability was the most common 
adverse event.Neuropsychiatric Disease and Treatment 2008:4(6) 1009
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Ten other patients, aged 28–48, with generalized 
epilepsy , including four with LGS were given LEV as 
compassionate use in a pilot prospective study. There was 
a mild or no effect on seizure reduction (Weber and Beran 
2004). Labate et al (2006) studied the effect of LEV in 
35 patients with refractory epilepsy, including two with 
LGS: seizure frequency improved in one and worsened in 
the other.
Pyridoxine (vitamin B6)
Since the initial description of this disorder in 1954, 
pyridoxine-dependent seizure has been recognized as a 
rare cause of refractory autosomal-recessive seizures in 
neonates. Diagnosis may be more difﬁ  cult in later onset 
cases when other seizure types have been described, 
including brief focal, atonic and myoclonic seizures or 
infantile spasms. Pyridoxine and pyridoxal phosphate 
have then been tested in the treatment of West syndrome 
and other conditions. Furthermore, Lee et al (2008) 
reported cases of LGS (25%) in patients with atypical 
mitochondriopathies and pyridoxine belongs to the 
so-called “mitochondrial coktail supplement” (vitamins B, 
C, E, coenzyme Q10 and L-carnitine). Pyridoxine, alone 
or as part of this cocktail, could be tried in refractory 
patients with cryptogenic LGS. In their assessment of LGS 
therapies published in 2000, Schmidt and Bourgeois (2000) 
already considered the use of pyridoxine as a fourth-line 
treatment.
Sulthiame (STM)
STM, already used as early as the 1960s (Garland and Sumner 
1964), is a carbonic anhydrase inhibitor responsible, at least 
partly, for beneﬁ  cial effects on epileptiform activity secondary 
to intraneuronal acidosis. It has been used in West syndrome 
with some success. Reports on its use in myoclonic epilepsies 
and as a sole AED are few and inconclusive, but in LGS, STM 
appears to be an efﬁ  cacious adjunct to currently-used agents 
(Lerman and Nussbaum 1975), at least in older studies. More 
recent use of STM is reserved to continuous SW during sleep 
syndromes and some idiopathic focal epilepsies. Indeed, 
one possible mechanism implicated in the development of 
cognitive deﬁ  cits is a pathologic enhancement of physiologi-
cal apoptotic neuronal death in the developing brain. Animal 
studies show that STM may signiﬁ  cantly enhance neuronal 
death in the developing rat brain (Manthey et al 2005). STM 
has the potential to precipitate acute psychotic episodes, 
especially in predisposed patients (Liske and Forster 1963). 
Therefore, continuous follow-up and careful use of this drug 
remain mandatory, especially in the pediatric population, 
although it is largely considered as safe.
Thyrotropin-releasing hormone (TRH)
TRH may act as an antiepileptic through a kynurenine 
mechanism, given that kynurenic acid acts as an antagonist on 
the NMDA receptor complex; however, the exact mechanism 
of action remains uncertain. TRH has been successfully used 
for treating neurologic disorders, including epilepsy with 
some success.
To conﬁ  rm this antiepileptic effect, 190 participants were 
included in an open-label, dose-ﬁ  nding, randomized study; 
98 of the patients, 2 years old, had a diagnosis of LGS. 
Forty-eight of the patients received a low dose of 0.4 mg/kg/day 
of TRH DN-1417 and were compared to 50 patients treated 
with the high dose of 1.6 mg/kg/day for 8 weeks. There was no 
signiﬁ  cant treatment effect for high dose TRH and no reported 
discontinuations due to adverse events (Inanaga et al 1989).
Tiagabine (TGB)
TGB is a selective competitive inhibitor of GAT1 that 
prevents GABA uptake. By slowing the reuptake of 
GABA, TGB prolongs inhibitory postsynaptic potentials. 
In preclinical studies, TGB increases the amount of time 
with SW discharges in absence models but shows some 
antiepileptic and neuroprotective effects in status models. 
It has been shown to be effective in focal seizures but 
non-convulsive SE and its very narrow spectrum limits 
clinical use, especially in LGS.
Zonisamide (ZNS)
ZNS is a broad-spectrum AED with a mechanism of action 
apparently based on its ability to block voltage-gated Na+ and 
T-type calcium channels. It shows a modest inhibitory effect 
on carbonic anhydrase probably unrelated to its antiepileptic 
action. It has been licensed as adjunctive treatment for focal 
seizures in adults.
Anecdotal improvement has been reported when ZNS 
is used as add-on therapy in pediatric epilepsy (Santos 
and Brotherton 2005) and in refractory LGS (Peters and 
Sorkin 1993; Glauser and Pellock 2002; You et al 2008a). 
Yagi (2004) analyzed the efﬁ  cacy of ZNS in 132 patients with 
LGS from pooled data grouping 1008 patients from controlled 
and uncontrolled Phase II and III studies and 726 from 
postmarketing studies: 32% of the patients had a 50% seizure 
reduction. The most frequent adverse events were drowsiness, 
ataxia, loss of appetite or gastrointestinal symptoms and 
slowing of mental activity.Neuropsychiatric Disease and Treatment 2008:4(6) 1010
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Antiepileptic drugs in development
Carisbamate (RWJ-333369)
Carisbamate is an investigational drug (Kulig and Malawska 
2007) with broad anticonvulsant activity in preclinical studies, 
elevating seizure threshold and preventing seizure spread. 
In animal models, it is effective in focal and generalized 
seizures, and may prevent the development of spontaneous 
recurrent epileptiform discharges and damage related to SE. 
The safety proﬁ  le seems encouraging as do results from initial 
studies in epileptic patients. In view of these properties, this 
AED could become a drug of choice for LGS.
Fluoro-felbamate
Fluorofelbamate, a dicarbamate, is a drug candidate in 
development, designed to retain the broad spectrum activity 
of FBM, but with a modiﬁ  ed metabolism that avoids the 
production of the reactive metabolite, aldehyde, believed 
to be the cause of the idiosyncratic life-threatening toxicity 
(Roecklein et al 2007; Bialer et al 2007). Results in vitro 
are promising and research is ongoing. If the better safety 
proﬁ  le of this AED is conﬁ  rmed, it could become a useful 
treatment in LGS.
Ganaxolone (GNX)
GNX belongs to a novel class of neurosteroids called epalons, 
which speciﬁ  cally modulate the GABA-A receptor in the 
CNS, acting through binding sites which are distinct from 
the BZD binding site. Chemically related to progesterone 
but devoid of any hormonal activity, the epalons have potent 
antiepileptic activities in animals. (Monghan et al 1997).
In view of its potential efﬁ  cacy and after preliminary 
encouraging results in patients (Laxer et al 2000; Pieribone 
et al 2007), clinical trials are planned in several epilepsy 
syndromes, including LGS (Perucca et al 2007).
Derivatives of LEV: brivaracetam and seletracetam
Brivaracetam (BRI) possesses a binding afﬁ  nity for the 
synaptic vesicle protein 2A (SV2A) that is ten-fold more 
powerful than LEV and also shows an ability to inhibit 
Na+ channels. Acute toxicity is low and the safety proﬁ  le 
in humans is favorable. BRI is primarily metabolized 
via hydrolysis of the acetamide group and by CYP2C8. 
Clearance of BRI is reduced in patients with hepatic 
insufﬁ  ciency and there is a potential for some drug-drug 
interactions (Bialer et al 2007, von Rosenstiel 2007). 
However, this drug could be promising in LGS because of 
its potential broad spectrum of action, in spite of probable 
drug-drug interactions.
Seletracetam (SEL) is another new pyrrolidone derivative 
structurally related to LEV (Bennet et al 2007; Bialer et al 
2007), discovered because of its high binding afﬁ  nity to 
the synaptic vesicle 2A (SV2A) protein. Pharmacokinetic 
studies in animals suggest a linear pharmacokinetics with 
no or mild metabolic interactions and a low plasma protein 
binding (10%). This suggests a low potential for drug-drug 
interactions. SEL shows very potent seizure suppression in 
different models of acquired or genetic epilepsy, suggesting 
a broad spectrum of activity and may be useful in LGS.
Remacemide (RMC)
RMC is a low-afﬁ  nity NMDA receptor blocker as well as 
Na+ channel blocker. The drug exerts anticonvulsant activity 
in various animal seizure models and in clinical studies 
(Malek et al 2003). In addition, the drug seems to provide 
some neuroprotection. In view of its potential broad spectrum 
of action, RMC could be useful in LGS.
Stiripentol (STP)
STP was ﬁ  rst identiﬁ  ed in 1978 with clinical trials starting 
in the 1980s in all forms of epileptic syndromes, including 
LGS in which it was used in combination with CBZ (Tran 
et al 1996). The LGS study BC-274, a single blind triphasic 
study showed a decrease in ﬁ  ts in 72% of the 24 participants 
aged 1–22 years. (http://www.emea.europa.eu/humandocs/
PDFs/EPAR/diacomit/H-664-en6.pdf).
STP was recently shown to increase GABA-ergic 
transmission (Quilichini et al 2006) in vitro in an experi-
mental immature rat model and to act as a direct allosteric 
modulator of the GABA receptor. Clinical studies were 
based on the fact that STP also acts as a powerful inhibitor of 
CYP3A4, CYP1A2, and CYP2C19, but gave disappointing 
results in adult patients. STP has been shown to be effective 
in atypical absences (Farwell et al 1993) and in myoclonic 
epilepsies, if combined with VPA and CLB (Chiron 2007). 
At the present time, STP is mainly used in Dravet and 
related syndromes added to CLB and VPA. However, the 
interactions of STP with a large number of drugs or toxic 
endogenous products need to be carefully considered from 
a long term safety perspective.
Other AEDs in development
Among the other numerous AEDs in the pipeline, VPA-like 
agents, such as diisopropyl acetamide (PID) and valrocemide 
are the most promising drugs in LGS because they 
have a similar broad spectrum of activity to VPA but fewer 
adverse events in terms of somnolence, weight problems and 
teratogenicity (Rogawski 2006).Neuropsychiatric Disease and Treatment 2008:4(6) 1011
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Immune treatments
Since the success of steroids in epileptic encephalopathy 
(Klein and Livingston 1950) and West syndrome (Sorel 
and Dusaucy-Bauloye 1958), these drugs have been 
systematically tried in refractory epilepsies, including LGS. 
Nevertheless, there have been few reports of steroid use in 
childhood epilepsy after the ﬁ  rst year of life. Some beneﬁ  ts 
have been previously reported with ACTH (Yamatogi et al 
1979) and corticosteroids (Roger et al 1989) in patients 
with LGS.
Prednisone was added to regular antiepileptic medications 
for the treatment of 28 children (aged 18 months to 10 years) 
with intractable epilepsy, including 10 with LGS. Seven of 
these patients became seizure free (Sinclair 2003). Other 
small series have been published in patients with intractable 
epilepsy, with different protocols, products and epilepsy 
syndromes, with various but often favorable results (Verhelst 
et al 2005). Side effects and lack of objective long-term 
effects have limited the use of steroids. Furthermore, new 
AEDs have become available since these older publications. 
However, Schmidt and Bourgeois (2000) consider the use of 
corticotrophin or corticosteroids as a fourth-line treatment in 
acute or subacute deterioration of LGS (You et al 2008b).
Intravenous immunoglobulins (IVIG)
The immune system has been sometimes called the “circulating 
brain” because of the numerous, reciprocal and continuous 
interactions between the immune and neurological systems 
(Billiau et al 2005). Consequently, the concept that the 
immune system may play an active role in epileptogenesis 
is more than 25 years old (Aarli and Fontana 1980) and has 
been developed in experimental animal models of epilepsy. 
Pechadre et al in 1977 noted that epileptic children treated 
with intramuscular immunoglobulins for recurrent infections 
had fewer seizures. Since this observation, Ariizumi et al 
(1983) reported a dramatic improvement in infants with 
West syndrome treated with IVIG while numerous studies 
have reported on the existence of a variety of immunological 
alterations, such as hypoIgA, in epileptic patients as well 
as the association of some well-known immune-mediated 
disease states, eg, lupus erythematous disease, with epilepsy 
(Duse et al 1996; van Rijckevorsel 1999; Aarli 2000). The link 
seems substantial in some epileptic syndromes, eg, Rasmussen 
disease, with the presence of autoantibodies and a favorable 
evolution after immunomodulatory treatments. However, the 
mechanisms of action of IVIG remain hypothetical (such as 
antiviral effect, substitutive therapy in case of concomitant 
immune deficiency, idiotype-anti-idiotype interaction, 
neuromodulant effect). The available data come mostly 
from open studies (van Rijckevorsel et al 1986; van Engelen 
et al 1994a; Billiau et al 2007), case reports (Fois et al 1990; 
Echenne et al 1991; Sterio et al 1992; Gross-Tsur et al 1993; 
Espinosa et al 2002), one single-blind (Ilum et al 1990) and one 
double-blind (van Rijckevorsel et al 1994). Doses, duration, 
and schedule of infusion, were different and results from the 
more than 370 treated children cannot be combined for a 
global analysis (van Engelen et al 1994b; Duse et al 1996; van 
Rijckevorsel 1999). However, the global review of published 
cases suggests that IVIG might be effective in some patients 
with refractory epilepsy, including LGS (Orange et al 2006; 
Feasby et al 2007).
Ketogenic and modiﬁ  ed Atkins diet
Descriptions of the beneﬁ  cial effects of fasting were already 
mentioned by Hippocrates and in the New Testament. Later, 
the concept of ‘diet’ evolved and it was clear that a high-fat 
diet can mimic ketosis secondary to fasting. The ketogenic 
diet was therefore “born” and ﬁ  rst developed in the 1920s 
(Swink et al 1997), when only a few AEDs were available. 
With the development of different AEDs this therapeutic 
option was used less frequently. This treatment may have 
serious long-term adverse effects and is difﬁ  cult to manage 
for prolonged periods (Hemingway et al 2001).
More recently, there has been new interest in this diet 
for use after failure of drug therapy, above all in children 
with refractory seizures (Kinsman et al 1992; Freeman et al 
1998; Freeman and Vining 1999; Lefevre and Aronson 
2000; Henderson et al 2006). Alternative ketogenic diets 
compared to the ﬁ  rst description have been proposed in order 
to improve long-term compliance and to decrease adverse 
events, notably on growth (for a review see Hartman and 
Vining 2007).
The ﬁ  rst published results may be difﬁ  cult to interpret 
because the description of clinical signs is limited and 
some patients with specific genetic disorders may be 
included, eg, GLUT-1 deﬁ  ciency syndrome characterized by 
intractable epilepsy (atonic seizure, myoclonus, absences), 
slow SW on EEG, mental retardation (Leary et al 2003) 
and highly responsive to ketogenic diet (Wexlet et al 
1997; Wang et al 2005). Nevertheless, Levy and Copper 
(2003) consider the diet as a possible option in the therapy 
of LGS.
Treatment of status epilepticus (SE)
Treatment of SE in LGS is the same as for other epileptic 
syndromes, at least for convulsive SE. However, BZDs Neuropsychiatric Disease and Treatment 2008:4(6) 1012
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should be used with caution because of the risk of worsening 
the status or precipitating tonic SE. EEG monitoring is 
recommended, especially if the patient does not recover 
consciousness. Non-convulsive SE may require special 
management, such as corticoids or a ketogenic diet (Dan 
and Boyd 2005).
Surgical treatment
Generalized symptomatic epilepsies with bilateral EEG 
abnormalities may be secondary to a focal lesion and 
be improved by surgery (Wyllie et al 2007). Because of 
refractoriness to medical treatment and severity of seizures, 
various surgical procedures, even in cryptogenic cases, have 
been developed to treat epileptic drop attacks, the most 
devastating seizures, including callosotomy, (multi)lobar 
disconnection, multiple subpial transections (Patil et al 2004) 
or protocols of vagus nerve or deep brain stimulation.
Furthermore, early surgery may improve the global 
prognosis of these children (Liu et al 2007).
Callosotomy
First described in 1940 by Van Wagenen and Herren, 
and previously recommended for epileptic drop attacks 
(tonic, atonic seizures) (Purves et al 1988; Nordgren et al 
1991) callosotomy shows a lower efﬁ  cacy for tonic-clonic 
seizures and is still considered as a palliative treatment. 
Early cases encountered severe complications, including 
hemispheric edema, mesial hemisphere infarcts, even death. 
Progress in new microsurgical techniques dramatically 
improved the safety of callosotomy. Complete callosotomy 
is recommended for children with severe mental handicap 
(Rathore et al 2007) while a two-third or three-fourth anterior 
disconnection is preferred in later onset LGS or in crypto-
genic cases with moderate mental handicap. Nevertheless, 
acute disconnection syndrome (reduction in verbal output, 
urinary incontinence, apathy, hemineglect) or callosal split 
syndrome (intermanual conﬂ  ict) may occur, temporarily for 
a few weeks or for more prolonged periods. Worsening of 
focal seizures may occur postoperatively.
Determinants of seizure outcome vary from one study to 
another. A better outcome has been related to the absence 
of focal abnormalities (Cukiert et al 2006), and a worse 
outcome to drop attacks associated with focal cerebral 
abnormality, to a greater mean duration of drop attacks, and 
to the presence of SW on EEG (Reutens et al 1993). Atypical 
absences have been noted to be dramatically improved in 
some reports (Machara et al 1996) but poorly inﬂ  uenced in 
other reports.
The degree of signiﬁ  cant improvement reported after 
callosotomy is highly variable, depending on the time 
of publication, the extent of disconnection, the selection 
of patients, the seizure type analyzed and so on. About 
two-thirds of patients have been signiﬁ  cantly improved after 
callosotomy (Purves et al 1988; Rougier et al 1997; Kwam 
et al 2006; Cukiert et al 2006), but this improvement can be 
lost over time.
Taken together, typical results consist of a (signiﬁ  cant) 
seizure reduction in 40% to 80% of patients, but speciﬁ  c 
effects on patients with LGS are rarely detailed. More 
recently, new surgical techniques, such as gamma knife 
(Pendl et al 1999; Eder et al 2006; Feichtinger et al 2006), 
have been developed for callosotomy (see below).
Vagus nerve stimulation (VNS)
VNS therapy was studied and approved in 1997 as add-on 
therapy in patients aged 12 years or older with refractory 
focal seizures. However, VNS should only be considered 
for patients who have been rejected for surgery or after 
surgery failure. There is however one exception to this 
general rule: VNS is now recommended before callosotomy. 
This recommendation is essentially based on subjective data 
but above all because VNS is fully reversible with fewer 
surgical risks compared to callosotomy.
Nonetheless, failure in one option can be improved by 
the second option, whatever the order. Both techniques are 
considered as palliative treatments and seem to have equal 
efﬁ  cacy (Karceski 2001; You et al 2007b) even if results 
are difﬁ  cult to analyze because of the multitude of different 
parameters.
Only a few adverse events related to surgery or to 
the device and stimulation have been reported, including 
infection, transient pain, voice alteration, and increased 
coughing as for other implanted patients. However, special 
care should be taken with patients who have swallowing 
difﬁ  culties, as stimulation may cause dysphagia and/or 
excessive salivation.
In LGS, VNS shows a 24%–42% global seizure reduction 
(Horning et al 1997; Lundgren et al 1998; Ben-Menachem 
et al 1999; Parker et al 1999; Hosain et al 2000; Frost et al 
2001; Aldemkamp et al 2002; Rychlicki et al 2006) with rare 
patients becoming seizure free (Parker et al 1999; Majoie 
et al 2001; Alexopoulos et al 2006). Some studies analyzed 
results from refractory childhood epilepsy including LGS, 
and it is not always possible to isolate data speciﬁ  c for LGS 
(Lundgren et al 1998; Parker et al 1999; Rychlicki et al 
2006). Results seem better in the group with less mental Neuropsychiatric Disease and Treatment 2008:4(6) 1013
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handicap at baseline, which could suggest that mental 
retardation may be a negative prognostic factor for VNS 
success. Improvement of alertness, even after long term 
follow-up, (Aldenkamp et al 2002) and QOL have also been 
described (Frost et al 2001).
Cortectomy/lobar disconnection
Some case reports have been published with selective 
cortectomy and sometimes spectacular results have been 
reported after surgery (You et al 2007a). Some LGS cases 
may be seizure free or free from disabling seizures after 
resective surgery (Quarato et al 2002), sometimes completed 
by subpial transections in the eloquent cortex. However, each 
case needs a personalized presurgical evaluation, sometimes 
including invasive video-EEG to ﬁ  nd the “driver” hemisphere 
and/or lobe (van Rijckevorsel et al 2006; Vaz et al 2008). 
From the published cases, the parietal (Angelini et al 1979; 
Quarato et al 2002) or frontal lobes (You et al 2007a; van 
Rijckevorsel et al 2006; Vaz et al 2008) are mainly involved 
in LGS.
Gamma-knife
Radiosurgery has been used for callosotomy (Pendl et al 
1999; Eder et al 2006; Feichtinger et al 2006). Short-term 
follow-up reports the same amount of seizure reduction 
as classical callosotomy with a seizure reduction of 60%, 
especially of drop attacks. Gamma-knife callosotomy seems 
safer for the early short term, but longer follow-up periods 
are needed to exclude the risk of secondary brain tumor or 
radionecrosis.
Multiple subpial transection (MST)
Multiple subpial transection (MST) is a new approach for 
epilepsy surgery, ﬁ  rst described by Morrell et al in 1989. 
MST can be an alternative to resection/disconnection when 
the epileptogenic zone transcends critical areas in the brain, 
and removal of the cortex may result in serious deﬁ  cits. MST 
is performed alone in functional areas or in combination 
with resection, cortectomy, lobe disconnection, etc. This 
technique is used in Landau-Kleffner and related syndromes 
and in focal epilepsies. However, anecdotal case reports in 
LGS suggest that these patients can improve dramatically 
after such surgery (Spencer et al 2002; Zhao et al 2003; van 
Rijckevorsel et al 2006; Vaz et al 2008).
Deep brain stimulation (DBS)
In the last 15 years, several clinical investigators (Velasco 
et al 1991) have considered stimulation therapy – broadly 
known as DBS – for targeting different subcortical 
structures such as the anterior thalamic nucleus, subthalamic 
nucleus, or amygdalohippocampus in patients with 
refractory epilepsy and rejected for epilepsy surgery. LGS 
patients, most of the time with a very broad deﬁ  nition of 
LGS, were included in some of these studies (Velasco et al 
1993; Velasco et al 2006) However, deﬁ  nitive conclusions 
regarding the optimal therapeutic target remain to be 
clariﬁ  ed.
The future
Neuroprotection
Although neuroprotection is successful only against some 
aspects of a complex cascade of multiple events during 
the repetition of seizures and the development of epilepsy, 
it might be a promising option in the treatment of refrac-
tory cases. Based on animal studies, some of the newer 
AEDs show possible neuroprotective activity in epilepsy 
(Stêpieñ et al 2005). However, to prevent epileptogenesis, 
interventions need to be directed against the processes 
implicated in the brain changes that underlie hyperexcit-
ability (Dichter et al 2002) and not only in the prevention 
of neuronal death. Animal studies have focused on SE or 
post-traumatic epilepsy models. Neuroprotection may not 
involve standard AEDs, but free radical scavengers to 
protect against oxidative injury, for example, or NMDA 
receptor antagonists.
In this regard, some papers have demonstrated 
possible neuroprotective effects of melatonin in the 
elderly (Han et al 2000) and in epilepsy (Chung et al 
2003), as well as an anticonvulsant effect (Peled 
et al 2001; Yildirim and Marangoz 2006). At the present 
time, there is no ongoing study of neuroprotection 
in LGS.
Gene therapy
Gene therapy is an old dream among epileptologists and 
neuroscientists (Freese et al 1997). Gene therapy represents, 
at the present time, an innovative and promising alternative 
for the treatment of refractory epileptic patients, especially 
if inaccessible to surgery. Several gene targets could 
be used to correct the balance between inhibitory and 
excitatory aspects of epilepsy with recombinant viral vectors 
(Freese et al 1997) or transduction of neuropeptide genes 
(Noe et al 2007).
Although the proof of concept may have been established, 
further investigations are required to demonstrate a Neuropsychiatric Disease and Treatment 2008:4(6) 1014
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therapeutic role of gene therapy in epilepsy and to evaluate 
safety concerns and possible side-effects.
Conclusions
The ultimate goal of epilepsy treatment is to achieve seizure 
control in a safe manner. Seizure freedom appears to be 
unrealistic in some refractory epilepsies, especially LGS. 
Four AEDs (FBM, LTG, TPM and RUF) have been ofﬁ  cially 
licensed for LGS after demonstrating signiﬁ  cant efﬁ  cacy in 
randomized, double-blind, placebo controlled studies. Older 
AEDs (especially VPA) are regularly used, based on more 
than 40 years of clinical practice.
Published results, even from randomized studies, are 
difﬁ  cult to compare. Each trial looked at different patient 
populations, with diverse co-medications and etiologies, and 
considered different outcomes for efﬁ  cacy. Unfortunately, 
a “magic pill” does not exist, and for that reason, other 
treatments are regularly tried.
For children with highly pharmacoresistant seizures, 
an individual and tailored treatment strategy is necessary 
(Figure 1), based on the likelihood of better seizure control 
and QOL balanced against the likely risks for each strategy 
(diet, stimulation, surgery, etc).
It is reasonable to consider non-medical treatments after 
failure of two to three AEDs. The different steps of this con-
tinuous therapeutic approach should depend on various factors, 
including patient characteristics, severity of seizures and mental 
handicap, and local availability of sophisticated techniques.
Psychiatric problems or severe mental handicap are no 
longer considered as contra-indications for surgery.
Multiple seizure types in a child with mental stagnation/regression 
Confirmation of LGS, research of etiologic factors 
Valproate 
Add-on of  Topiramate or Rufinamide or Lamotrigine 
Felbamate
Presurgical evaluation 
Focal or regional lesions  No lesion 
Surgery: resection, 
disconnection, multiple 
subpial transections, etc. 
VNS 
Ketogenic diet 
Callosotomy
Several subsequent 
medication trials with a 
maximum of 3 chronic 
antiepileptic drugs
Off-label or in 
development 
antiepileptic drugs 
Figure 1 Treatment strategy for children with highly pharmacoresistant seizures.Neuropsychiatric Disease and Treatment 2008:4(6) 1015
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The worst approach to patients with LGS is one of 
pessimism, considering that the prognosis is deﬁ  nitively 
catastrophic. On the other hand, the reverse attitude with 
iterative aggressive treatments should also be avoided. 
A better strategy is to explain regularly to the family that the 
aim of the treatment is to suppress the most severe seizures, 
to avoid additional comorbidities and to avoid heavy poly-
therapy. The situation has to be regularly re-evaluated.
As LGS is rare, case reports of atypical or unusual 
treatments may help other clinicians in deciding what type 
of treatment to use in difﬁ  cult cases.
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